Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henry M Kuerer

Showing results (1-10 of 358) with videos related to

Pageof 36
Sort By:
Annals of Surgical Oncology|August 24, 2022
Moving Forward with Omission of Breast Cancer Surgery Following Neoadjuvant Systemic TherapyHenry M Kuerer
The Lancet. Oncology|September 10, 2018
More evidence for further minimisation of breast-cancer surgeryHenry M Kuerer
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 6, 2018
Navigating treatment controversies for DCIS in the era of genomic profiling and active surveillance trialsHenry M Kuerer
The Lancet. Oncology|December 15, 2010
Rational individualised selection of adjuvant therapy for ductal carcinoma in situHenry M Kuerer
Annals of Surgical Oncology|September 24, 2005
If at first or second you don't succeed: mastectomy?Henry M Kuerer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2016
Proceed With Caution: Concerns Related to Routine Internal Mammary Lymph Node Radiation for Node-Positive Breast CancerHenry M Kuerer
International Journal of Clinical Oncology|May 19, 2026
Essential details regarding the new omission of breast cancer surgery paradigm and the analysis of the JCOG 1806 trialHenry M Kuerer
Annals of Surgical Oncology|July 28, 2018
Increasing Breast Cancer Systemic Therapy Use Before Surgery in the United States: Scaling Down and the Promise of Selective Elimination of SurgeryHenry M Kuerer
Expert Review of Anticancer Therapy|May 5, 2015
Ductal carcinoma in situ: treatment or active surveillance?Henry M Kuerer
JAMA Oncology|July 24, 2025
Five Years After Pathologic Complete Response Without Surgery-ReplyHenry M Kuerer
Pageof 36

Showing results (1-10 of 358) with videos related to

Sort By:
Pageof 36
Annals of Surgical Oncology|August 24, 2022
Moving Forward with Omission of Breast Cancer Surgery Following Neoadjuvant Systemic TherapyHenry M Kuerer
The Lancet. Oncology|September 10, 2018
More evidence for further minimisation of breast-cancer surgeryHenry M Kuerer
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 6, 2018
Navigating treatment controversies for DCIS in the era of genomic profiling and active surveillance trialsHenry M Kuerer
The Lancet. Oncology|December 15, 2010
Rational individualised selection of adjuvant therapy for ductal carcinoma in situHenry M Kuerer
Annals of Surgical Oncology|September 24, 2005
If at first or second you don't succeed: mastectomy?Henry M Kuerer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2016
Proceed With Caution: Concerns Related to Routine Internal Mammary Lymph Node Radiation for Node-Positive Breast CancerHenry M Kuerer
International Journal of Clinical Oncology|May 19, 2026
Essential details regarding the new omission of breast cancer surgery paradigm and the analysis of the JCOG 1806 trialHenry M Kuerer
Annals of Surgical Oncology|July 28, 2018
Increasing Breast Cancer Systemic Therapy Use Before Surgery in the United States: Scaling Down and the Promise of Selective Elimination of SurgeryHenry M Kuerer
Expert Review of Anticancer Therapy|May 5, 2015
Ductal carcinoma in situ: treatment or active surveillance?Henry M Kuerer
JAMA Oncology|July 24, 2025
Five Years After Pathologic Complete Response Without Surgery-ReplyHenry M Kuerer
Pageof 36